Exosome micro RNAs as liquid biopsy biomarkers to follow-up skin melanomas patients

iToBoS presented through the poster "Exosome micro RNAs as liquid biopsy biomarkers to follow-up skin melanomas patients".

Cutaneous melanoma (CM) incidence is increasingly growing mainly among Caucasians and early diagnosis with patients’ risk categories is crucial for an appropriate tumor management. New tools are needed to discriminate high from low risk melanomas at diagnosis and to follow up high risk patients. The project iToBoS is dealing with the first topic, while liquid biopsy can be used for CM monitoring and treatment response evaluation. There is a urgent need of new biomarkers to follow-up patient with CM negative for BRAF and/or NRAS hot spot mutations.

In a multicentre study, plasma was collected from 48 patients with melanoma and age and gender matched with controls without melanoma. The expression of seven microRNAs (hsa-miR-149-3p, hsa-miR-134-5p, hsa-miR-200c-3p, hsa-miR-144-3p, hsa-miR-21-5p and hsa-miR-150-5p) was quantified by qPCR and data analysis was carried out applying the 2-^ΔΔCt method. Nonparametric test were used for statistical elaboration (GraphPad Prism 8.0; San Diego, CA 92108, USA).

Learn more at Exosome micro RNAs as liquid biopsy biomarkers to follow-up skin melanomas patients.